Rapid Dose Therapeutics FY23 Revenue Declines 59%, Here Are The Details
Portfolio Pulse from Vuk Zdinjak
Rapid Dose Therapeutics Corp. (OTCPK:RDTCF) (CSE:DOSE) reported a 59% decrease in revenue for FY23, with a net comprehensive loss of CA$3.8 million. The company established B2B partnerships to sell their nutraceutical products in Canadian retail stores and entered into a pharmaceutical collaboration with Skycare Compounding Labs. However, they faced regulatory approval hurdles and delays for product applications in Europe, USA, and Canada.
June 29, 2023 | 2:45 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Rapid Dose Therapeutics reported a significant decrease in revenue and a net loss for FY23. Despite new partnerships and collaborations, the company faced regulatory hurdles which could impact future performance.
The company's financial performance has declined significantly compared to the previous year. Despite efforts to expand their customer base and establish new collaborations, they have faced regulatory hurdles which could impact their ability to distribute products and generate revenue in the future.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100